Market research
4AB.F AbbVie Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 402B
- P/E ratio
- 75.33
- Analyst target
- 127.01
- Dividend yield
- 3.0%
- Beta
- 0.28
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- ISIN
- US00287Y1091
- Market cap
- 402B
- P/E ratio
- 75.33
- Analyst target
- 127.01
- Dividend yield
- 3.0%
- Beta
- 0.28
About
About AbbVie Inc
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 4AB.F discussion.
5 years, 4 months ago
AbbVie Inc is currently in a long term uptrend where the price is trading 11.3% above its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.9.
AbbVie Inc's total revenue rose by 59.2% to $14B since the same quarter in the previous year.
Its net income has dropped by 98.7% to $36M since the same quarter in the previous year.
Finally, its free cash flow grew by 47.0% to $5B since the same quarter in the previous year.
Based on the above factors, AbbVie Inc gets an overall score of 4/5.